

November 1, 2023

Pfizer, Inc.
Attention: Karen Baker
Director, Global Regulatory Affairs
235 East 42nd Street
New York, NY 10017-5755

RE: Emergency Use Authorization 105

Dear Ms. Baker:

This letter is in response to Pfizer, Inc.'s (Pfizer) request that the Food and Drug Administration (FDA or Agency) issue an Emergency Use Authorization (EUA) for the emergency use of PAXLOVID (nirmatrelvir co-packaged with ritonavir) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in certain adults and pediatric patients pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3).

On February 4, 2020, as amended on March 15, 2023, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency, or a significant potential for a public health emergency, that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes coronavirus disease 2019 (COVID-19).¹ On the basis of such determination, the Secretary of HHS on March 27, 2020, declared that circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic, pursuant to Section 564 of the Act (21 U.S.C. 360bbb-3), subject to terms of any authorization issued under that section.²

On December 22, 2021, the FDA issued an EUA for emergency use of PAXLOVID for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and

¹ U.S. Department of Health and Human Services, *Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3. February 4, 2020; U.S. Department of Health and Human Services, *Amended Determination of a Public Health Emergency or Significant Potential for a Public Health Emergency Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3(b). March 15, 2023. 88 FR 16644 (March 20, 2023) (“Amended Determination”).

² U.S. Department of Health and Human Services, *Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act*, 21 U.S.C. § 360bbb-3, 85 FR 18250 (April 1, 2020). See Amended Determination (“The declarations issued pursuant to section 564(b)(1) of the FD&C Act that circumstances exist justifying the authorization of emergency use of certain in vitro diagnostics, personal respiratory protective devices, other medical devices and drugs and biological products, as set forth in those declarations, and that are based on the February 4, 2020 determination, remain in effect until those declarations are terminated in accordance with section 564 of the FD&C Act.”).

older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. At that time, PAXLOVID was not FDA-approved for any indication.

PAXLOVID is comprised of nirmatrelvir, a SARS-CoV-2 main protease inhibitor (M^{Pro}; also referred to as 3CL^{Pro} or nsp5 protease), co-packaged with ritonavir, an HIV-1 protease inhibitor and CYP3A inhibitor. Ritonavir, which has no activity against SARS-CoV-2 on its own, is included to inhibit the CYP3A-mediated metabolism of nirmatrelvir and consequently increase nirmatrelvir plasma concentrations to levels anticipated to inhibit SARS-CoV-2 replication.

FDA subsequently reissued the Letter of Authorization (LOA) on March 17, 2022³, April 14, 2022⁴, July 6, 2022⁵, August 5, 2022⁶, October 27, 2022⁷, February 1, 2023⁸, and May 25, 2023⁹.

On May 25, 2023, FDA approved NDA 217188 for PAXLOVID, which is indicated for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

³ In its March 17, 2022 revision, FDA revised the LOA to add a new condition of authorization regarding registration and listing. Condition H in the LOA was also revised to require Pfizer to recall distributed product, upon request by FDA, in the event a significant quality problem is identified that impacts already distributed PAXLOVID.

⁴ In its April 14, 2022 revision, FDA revised the LOA to authorize an additional dose pack presentation of PAXLOVID with appropriate dosing for patients within the scope of this authorization with moderate renal impairment. Corresponding revisions were also incorporated into the “How Supplied” section of the Fact Sheet for Healthcare Providers.

⁵ In its July 6, 2022 revision, FDA authorized state-licensed pharmacists to prescribe PAXLOVID subject to certain conditions detailed in Section II (Scope of Authorization) of this LOA. Corresponding revisions were also incorporated into the Fact Sheet for Healthcare Providers. Updates were also incorporated to certain post-authorization requirements detailed in Condition O of this letter.

⁶ In its August 5, 2022 revision, FDA revised the LOA to add new post-authorization requirements in Condition O of this letter for Pfizer to conduct a clinical trial in patients with “COVID-19 rebound” and a clinical trial evaluating different durations of treatment in immunocompromised patients with mild-to-moderate COVID-19. The Fact Sheet for Patients, Parents, and Caregivers was also revised to include additional clarifying information on how to take PAXLOVID, which included pictures of packaging and tablets for both dosing presentations.

⁷ In its October 27, 2022 revision, FDA incorporated clarifying revisions to Condition X of this letter. Condition W was also revised to require that all printed matter, advertising and promotional materials relating to the use of PAXLOVID under this authorization be submitted to FDA for consideration at least 14 calendar days prior to initial dissemination or first use.

⁸ In its February 1, 2023 revision, FDA revised the scope of authorization to no longer require positive results of direct SARS-CoV-2 viral testing. As revised, the scope of authorization required, in addition to other requirements, that adults and pediatric patients (12 years of age and older weighing at least 40 kg) have a current diagnosis of mild-to-moderate COVID-19. Corresponding changes were also made to the authorized Fact Sheets. Condition O in this letter was also revised based on the completion of a post-authorization requirement. The Fact Sheet for Healthcare Providers was also revised to reflect the current indication for Veklury, an approved alternative to Paxlovid, and to include new information on drug-drug interactions.

⁹ In its May 25, 2023, revision, FDA revised condition L on the monitoring and analysis of SARS-CoV-2 variants, and to remove certain post-authorization requirements from this LOA that are adequately addressed as post-market requirements or post-market commitments associated with the approval of NDA 217188. Corresponding revisions, when appropriate, were incorporated into the authorized Fact Sheets. The authorized Fact Sheet for Healthcare Providers was also revised to include a boxed warning on the identification of and assessment for drug-drug interactions with PAXLOVID. Relevant information on drug-drug interactions was also incorporated in the Fact Sheet for Patients, Parents and Caregivers.

On November 1, 2023, having concluded that revising this EUA is appropriate to protect the public health or safety under Section 564(g)(2) of the Act, FDA is reissuing the May 25, 2023 letter in its entirety, to revise the scope of authorization to no longer require the distribution of PAXLOVID under this EUA to be directed by the United States Government. The scope of authorization was also revised to authorize the emergency use of PAXLOVID labeled and packaged in accordance with NDA 217188 for the treatment of mild-to-moderate COVID-19 in certain pediatric patients. Corresponding revisions have been incorporated to the Fact Sheet for Health Care Providers and Fact Sheet for Patients, Parents and Caregivers. Post-authorization requirements, formerly condition L in this LOA, have also been removed as they are redundant with post-market requirements associated with the approved NDA for Paxlovid. Clarifying edits have also been incorporated to conditions H and I of this LOA.

Based on the totality of scientific evidence available to FDA, including data from the clinical trial EPIC-HR (NCT04960202), a Phase 2/3 randomized, double blind, placebo-controlled clinical trial, it is reasonable to believe that PAXLOVID may be effective for the treatment of mild-to-moderate COVID-19, as described in the Scope of Authorization (Section II), and when used under the conditions described in this authorization, the known and potential benefits of PAXLOVID outweigh the known and potential risks of such product.

Having concluded that the criteria for issuance of this authorization under Section 564(c) of the Act are met, I am authorizing the emergency use of PAXLOVID for the treatment of mild-to-moderate COVID-19, as described in the Scope of Authorization section of this letter (Section II) and subject to the terms of this authorization.

I. Criteria for Issuance of Authorization

I have concluded that the emergency use of PAXLOVID for the treatment of COVID-19, when administered as described in the Scope of Authorization (Section II), meets the criteria for issuance of an authorization under Section 564(c) of the Act, because:

1. SARS-CoV-2 can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;
2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that PAXLOVID may be effective for the treatment of mild-to-moderate COVID-19, as described in the Scope of Authorization (Section II), and that, when used under the conditions described in this authorization, the known and potential benefits of PAXLOVID outweigh the known and potential risks of such product; and
3. There is no adequate, approved, and available alternative to the emergency use of PAXLOVID for the treatment of mild-to-moderate COVID-19.^{10,11}

¹⁰ No other criteria of issuance have been prescribed by regulation under Section 564(c)(4) of the Act.

¹¹ Veklury (remdesivir) is an FDA-approved alternative to PAXLOVID when used for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. Veklury is administered via intravenous infusion for a total treatment duration of 3 days. Although Veklury is an FDA-approved alternative to

II. Scope of Authorization

I have concluded, pursuant to Section 564 of the Act, that the scope of this authorization is limited as follows:

- PAXLOVID, as described in Category A¹² of the Product Description section of this letter, is authorized for emergency use by healthcare providers for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death;
- PAXLOVID, as described in Category B¹³ of the Product Description section of this letter, is authorized for emergency use by healthcare providers for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death;

Limitations on Authorized Use

- PAXLOVID is not authorized for use as pre-exposure or as post-exposure prophylaxis for prevention of COVID-19.
- PAXLOVID may be prescribed for the emergency uses authorized for a product in Category A and Category B, as described above, by physicians, advanced practice registered nurses, and physician assistants licensed or authorized under state¹⁴ law to prescribe drugs. In addition, PAXLOVID may be prescribed for an individual patient by a state-licensed pharmacist for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death, in accordance with the FDA-approved Prescribing Information or authorized labeling, as applicable, and subject to the following conditions:
 - Sufficient information is available, such as through access to health records less than 12 months old or consultation with a health care provider in an

PAXLOVID as described above, FDA does not consider Veklury to be an adequate alternative to PAXLOVID for this authorized use because it may not be feasible or practical for certain patients (e.g., it requires an intravenous infusion daily for 3 days). Additionally, although different presentations of PAXLOVID are now FDA-approved for the treatment of mild-to-moderate COVID-19 in certain adults, there are not sufficient quantities of the approved PAXLOVID available for distribution to the authorized adult population in its entirety at the time of reissuance of the EUA, and PAXLOVID is not FDA-approved for individuals younger than 18 years of age.

¹² The presentations of PAXLOVID described in Category A of the Product Description section of this letter are those that are labeled and packaged in accordance with EUA 105.

¹³ The presentations of PAXLOVID described in Category B of the Product Description section of this letter are those that are labeled and packaged in accordance with NDA 217188.

¹⁴ The term “State” includes any State or Territory of the United States, the District of Columbia, and the Commonwealth of Puerto Rico. See Section 201(a)(1) of the Act.

established provider-patient relationship with the individual patient, to assess renal and hepatic function; and

- Sufficient information is available, such as through access to health records, patient reporting of medical history, or consultation with a health care provider in an established provider-patient relationship with the individual patient, to obtain a comprehensive list of medications (prescribed and non-prescribed) that the patient is taking to assess for potential drug interaction.
- The use of PAXLOVID covered by this authorization must be in accordance with the authorized Fact Sheets.

Product Description

PAXLOVID consists of 150 mg tablets of nirmatrelvir that are co-packaged with 100 mg tablet ritonavir.

PAXLOVID is authorized to be distributed in the following presentations:

Category A¹⁵

- *300 mg nirmatrelvir; 100 mg ritonavir*: Each carton contains 30 tablets divided in 5 daily-dose blister cards. Each blister card contains 4 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each). Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card. Each carton and individual blister card include the following statement: “For use under Emergency Use Authorization.” NDC: 0069-1085-30, 0069-1085-06, 0069-0345-30, 0069-0345-06.
- *150 mg nirmatrelvir; 100 mg ritonavir*¹⁶: Each carton contains 20 tablets divided in 5 daily-dose blister cards. Each blister card contains 2 nirmatrelvir tablets (150 mg each) and 2 ritonavir tablets (100 mg each). Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card. Each carton and individual blister card include the following statement: “For use under Emergency Use Authorization.” NDC: 0069-1101-20, 0069-1101-04.

Category B¹⁷

- *300 mg nirmatrelvir; 100 mg ritonavir*: Each carton contains 30 tablets divided in 10 daily-dose blister cards. Each blister card contains 2 nirmatrelvir tablets (150 mg each) and 1 ritonavir tablets (100 mg each). Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card.

¹⁵ Supra at Note 12.

¹⁶ The 150 mg nirmatrelvir; 100 mg ritonavir presentation is designed to provide appropriate dosing for patients within the scope of this authorization with moderate renal impairment. See section 2.2 of the Fact Sheet for Healthcare Providers for more information.

¹⁷ Supra at Note 13.

NDC: 0069-5321-30, 0069-5001-30, 0069-5045-30, 0069-5001-06, 0069-5045-06, 0069-5321-03.

- *150 mg nirmatrelvir; 100 mg ritonavir*¹⁸: Each carton contains 20 tablets divided in 10 daily-dose blister cards. Each blister card contains 1 nirmatrelvir tablets (150 mg each) and 1 ritonavir tablets (100 mg each). Nirmatrelvir tablets and ritonavir tablets are supplied in separate blister cavities within the same child-resistant blister card. NDC: 0069-5017-20, 0069-5317-20, 0069-5017-04, 0069-5317-02

The authorized storage and handling information for PAXLOVID is included in the authorized Fact Sheet for Healthcare Providers.

PAXLOVID is authorized for emergency use with the following product-specific information required to be made available to healthcare providers and to patients, parents, and caregivers, respectively, through Pfizer’s website www.COVID19oralRX.com (referred to as the “authorized labeling”):

- Fact Sheet for Healthcare Providers: Emergency Use Authorization (EUA) for PAXLOVID
- Fact Sheet for Patients, Parents and Caregivers: Emergency Use Authorization (EUA) of PAXLOVID for Coronavirus Disease 2019 (COVID-19)

I have concluded, pursuant to Section 564(d)(2) of the Act, that it is reasonable to believe that the known and potential benefits of PAXLOVID, when used for the treatment of mild-to-moderate COVID-19 in accordance with this Scope of Authorization (Section II), outweigh the known and potential risks.

I have concluded, pursuant to Section 564(d)(3) of the Act, based on the totality of scientific evidence available to FDA, that it is reasonable to believe that PAXLOVID may be effective for the treatment of mild-to-moderate COVID-19 in accordance with this Scope of Authorization (Section II), pursuant to Section 564(c)(2)(A) of the Act.

Having reviewed the scientific information available to FDA, including the information supporting the conclusions described in Section I above, I have concluded that PAXLOVID (as described in this Scope of Authorization (Section II)) meets the criteria set forth in Section 564(c) of the Act concerning safety and potential effectiveness.

The emergency use of PAXLOVID under this EUA must be consistent with, and may not exceed, the terms of the Authorization, including the Scope of Authorization (Section II) and the Conditions of Authorization (Section III). Subject to the terms of this EUA and under the circumstances set forth in the Secretary of HHS's determination under Section 564(b)(1)(C) described above and the Secretary of HHS’s corresponding declaration under Section 564(b)(1), PAXLOVID is authorized for the treatment of mild-to-moderate COVID-19, as described in the Scope of Authorization (Section II) under this EUA, despite the fact that it does not meet certain requirements otherwise required by applicable federal law.

¹⁸ Supra at Note 16.

III. Conditions of Authorization

Pursuant to Section 564 of the Act, I am establishing the following conditions with respect to the emergency use of PAXLOVID as described in the Scope of Authorization (Section II)¹⁹:

Pfizer and Authorized Distributors²⁰

- A. Pfizer and authorized distributor(s) will ensure that PAXLOVID is distributed and the authorized labeling (i.e., Fact Sheets) will be made available to healthcare facilities and/or healthcare providers as described in Section II of this Letter of Authorization.
- B. Pfizer and authorized distributor(s) will ensure that appropriate storage is maintained until the product is delivered to healthcare facilities and/or healthcare providers.
- C. Pfizer and authorized distributor(s) will ensure that the terms of this EUA are made available to all relevant stakeholders (e.g., U.S. government agencies, state and local government authorities, authorized distributors, healthcare facilities, healthcare providers) involved in distributing or receiving PAXLOVID. Pfizer will provide to all relevant stakeholders a copy of this Letter of Authorization and communicate any subsequent amendments that might be made to this Letter of Authorization and its authorized accompanying materials (i.e., Fact Sheets).
- D. Pfizer may request changes to this authorization, including to the authorized Fact Sheets for PAXLOVID. Any request for changes to this EUA must be submitted to the Office of Infectious Diseases/Office of New Drugs/Center for Drug Evaluation and Research. Such changes require appropriate authorization prior to implementation.²¹
- E. Pfizer may develop and disseminate instructional and educational materials (e.g., materials providing information on product administration and/or patient monitoring) that are consistent with the authorized emergency use of PAXLOVID as described in this Letter of Authorization and authorized labeling, without FDA's review and concurrence, when necessary to meet public health needs. Any instructional and educational materials that are inconsistent with the authorized labeling for PAXLOVID are prohibited. If the Agency notifies Pfizer that any instructional and educational materials are inconsistent with the

¹⁹ This EUA does not restrict the distribution or administration of PAXLOVID, as described in Category B of the Product Description section, when it is distributed or administered for its approved use.

²⁰ "Authorized Distributor(s)" are identified by Pfizer as an entity or entities allowed to distribute authorized PAXLOVID.

²¹ The following types of revisions may be authorized without reissuing this letter: (1) changes to the authorized labeling; (2) non-substantive editorial corrections to this letter; (3) new types of authorized labeling, including new fact sheets; (4) new carton/container labels; (5) expiration dating extensions; (6) changes to manufacturing processes, including tests or other authorized components of manufacturing; (7) new conditions of authorization to require data collection or study; (8) new strengths of the authorized product, new product sources (e.g., of active pharmaceutical ingredient) or of product components. For changes to the authorization, including the authorized labeling, of the type listed in (3), (6), (7), or (8), review and concurrence is required from the Counter-Terrorism and Emergency Coordination Staff/Office of the Center Director/CDER and the Office of Counterterrorism and Emerging Threats/Office of the Chief Scientist.

authorized labeling, Pfizer must cease distribution of such instructional and educational materials. Furthermore, as part of its notification, the Agency may also require Pfizer to issue corrective communication(s).

- F. Pfizer will report to FDA all serious adverse events and medication errors potentially related to PAXLOVID use that are reported to Pfizer using either of the following options.

Option 1: Submit reports through the Safety Reporting Portal (SRP) as described on the [FDA SRP](#) web page.

Option 2: Submit reports directly through the Electronic Submissions Gateway (ESG) as described on the [FAERS electronic submissions](#) web page.

Submitted reports under both options must state: “PAXLOVID use for COVID-19 under Emergency Use Authorization (EUA).” For reports submitted under Option 1, include this language at the beginning of the question “Describe Event” for further analysis. For reports submitted under Option 2, include this language at the beginning of the “Case Narrative” field.

- G. All manufacturing, packaging, and testing sites for both drug substance and drug product will comply with current good manufacturing practice requirements of Section 501(a)(2)(B) of the Act.
- H. Pfizer will submit information to the Agency within three working days of receipt of any information concerning significant quality problems with distributed drug product of PAXLOVID that includes the following:
- Information concerning any incident that causes the drug product or its labeling to be mistaken for, or applied to, another article; or
 - Information concerning any microbiological contamination, or any significant chemical, physical, or other change or deterioration in the distributed drug product, or any failure of one or more distributed batches of the product to meet the established specifications.

If a significant quality problem affects unreleased product and may also impact product(s) previously released and distributed, then information must be submitted for all potentially impacted lots.

Pfizer will include in its notification to the Agency whether the batch, or batches, in question will be recalled. If FDA requests that batches of PAXLOVID, as described in Category A of the Product Description section of this letter, at any time, be recalled, Pfizer must recall them.

If not included in its initial notification, Pfizer must submit information confirming that Pfizer has identified the root cause of the significant quality problems, taken corrective action, and provide a justification confirming that the corrective action is appropriate and

effective. Pfizer must submit this information as soon as possible but no later than 45 calendar days from the initial notification.

- I. Pfizer will manufacture PAXLOVID, as described in Category A of the Product Description section of this letter, to meet all quality standards and per the manufacturing process and control strategy as detailed in Pfizer’s EUA request. Pfizer will not implement any changes to the description of the product, manufacturing process, facilities and equipment, and elements of the associated control strategy that assure process performance and quality of the authorized product, without notification to and concurrence by the Agency as described under Condition D.
- J. Pfizer will list each presentation of PAXLOVID with a unique product NDC under the marketing category of Emergency Use Authorization. Further, the listing will include each establishment where manufacturing is performed for the drug and the type of operation performed at each such establishment.
- K. Through a process of inventory control, Pfizer and authorized distributor(s) will maintain records regarding distribution of PAXLOVID (i.e., lot numbers, quantity, receiving site, receipt date).
- L. Pfizer shall provide samples as requested of the authorized nirmatrelvir to HHS for evaluation of activity against emerging global viral variants of SARS-CoV-2, including specific amino acid substitution(s) of interest (e.g., variants that are highly prevalent or that harbor substitutions in the target protein(s) or target cleavage sites) within 5 business days of any request made by HHS. Analyses performed with the supplied quantity of authorized nirmatrelvir may include, but are not limited to, cell culture potency assays, biochemical assays, and in vivo efficacy assays.
- M. Pfizer and authorized distributor(s) will make available to FDA upon request any records maintained in connection with this EUA.

Healthcare Facilities to Whom PAXLOVID Is Distributed and Healthcare Providers Administering PAXLOVID

- N. Healthcare facilities and healthcare providers will ensure that they are aware of the Letter of Authorization, and the terms herein, and that the authorized Fact Sheets are made available to healthcare providers and to patients, parents, and caregivers, respectively, through appropriate means, prior to administration of PAXLOVID.
- O. Healthcare facilities and healthcare providers receiving PAXLOVID will track all serious adverse events and medication errors that are considered to be potentially related to PAXLOVID use and must report these to FDA in accordance with the Fact Sheet for Healthcare Providers. Complete and submit a MedWatch form (www.fda.gov/medwatch/report.htm), or complete and submit FDA Form 3500 (health professional) by fax (1-800-FDA-0178) (these forms can be found via link above). Call [1-800-FDA-1088](tel:1-800-FDA-1088) for questions. Submitted reports must state, “PAXLOVID use for COVID-

19 under Emergency Use Authorization” at the beginning of the question “Describe Event” for further analysis. A copy of the completed FDA Form 3500 must also be provided to Pfizer per the instructions in the authorized labeling.

- P. Healthcare facilities and healthcare providers will ensure that appropriate storage is maintained until the product is administered consistent with the terms of this letter and the authorized labeling.
- Q. Through a process of inventory control, healthcare facilities will maintain records regarding the dispensing and administration of PAXLOVID for the use authorized in this letter (i.e., lot numbers, quantity, receiving site, receipt date), product storage, and maintain patient information (e.g., patient name, age, disease manifestation, number of doses administered per patient, other drugs administered).
- R. Healthcare facilities will ensure that any records associated with this EUA are maintained until notified by Pfizer and/or FDA. Such records will be made available to Pfizer, HHS, and FDA for inspection upon request.
- S. Healthcare facilities and providers will report therapeutics information and utilization data as directed by HHS.

Conditions Related to Printed Matter, Advertising, and Promotion

- T. All descriptive printed matter, advertising, and promotional materials relating to the use of PAXLOVID under this authorization shall be consistent with the authorized labeling, as well as the terms set forth in this EUA, and meet the requirements set forth in Section 502(a) and (n) of the Act, as applicable, and FDA implementing regulations. References to “approved labeling”, “permitted labeling”, or similar terms in these requirements shall be understood to refer to the authorized labeling for the use of PAXLOVID under this authorization. In addition, such materials shall:
 - Be tailored to the intended audience.
 - Not take the form of reminder advertisements or reminder labeling, as those terms are described in 21 CFR 202.1(e)(2)(i) and 21 CFR 201.100(f), respectively, except that reminder advertisements and reminder labeling intended only to provide price information to consumers, as described in 21 CFR 200.200, are permissible so long as such materials meet all conditions described in 21 CFR 200.200(a)(1)-(a)(4).
 - Present the same risk information relating to the major side effects and contraindications concurrently in the audio and visual parts of the presentation for advertising and promotional materials in audio-visual format.
 - Be accompanied by the authorized labeling, if the promotional materials are not subject to Section 502(n) of the Act.
 - Be submitted to FDA accompanied by Form FDA-2253 for consideration at least 14 calendar days prior to initial dissemination or first use.

- U. Pfizer may disseminate descriptive printed matter, advertising, and promotional materials relating to the emergency use of PAXLOVID that provide accurate descriptions of safety results and efficacy results on a clinical endpoint(s) from the clinical trial(s) summarized in the authorized labeling. Such materials must include any limitations of the clinical trial data as described in the authorized labeling. Pfizer may not imply that PAXLOVID is FDA-approved for its authorized use in the pediatric patient population as detailed in the Scope of Authorization (Section II) by making statements such as “PAXLOVID is safe and effective for the treatment of COVID-19 in pediatric patients.”
- V. All descriptive printed matter, advertising, and promotional material, relating to the use of PAXLOVID under this authorization clearly and conspicuously shall state that:
- PAXLOVID has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death; and
 - The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.

If the Agency notifies Pfizer that any descriptive printed matter, advertising, or promotional materials do not meet the terms set forth in Conditions T through V of this EUA, Pfizer must cease distribution of such descriptive printed matter, advertising, or promotional materials in accordance with the Agency’s notification. Furthermore, as part of its notification, the Agency may also require Pfizer to issue corrective communication(s).

IV. Duration of Authorization

This EUA will be effective until the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

Sincerely,

Patrizia A.
Cavazzoni -S

Digitally signed by
Patrizia A. Cavazzoni -S
Date: 2023.11.01
11:53:33 -04'00'

Patrizia Cavazzoni, M.D.
Director
Center for Drug Evaluation and Research
U.S. Food and Drug Administration